Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Dulera by Year
Dulera (mometasone/formoterol, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)
Merck Dulera: $186M in FY2018, down 28.7% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2018
186
Period ended Dec 31, 2018
Change on a year earlier
-28.7%
261 in FY2017
History
3 years
Since FY2016
Sources
1
Form 10-K (filed 2019-02-27)
Where the FY2018 figure comes from
Source: Form 10-K (filed 2019-02-27) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Dulera (mometasone/formoterol, legacy pre-Organon spin-off) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2018 | Dec 31, 2018 | 186 | -28.7% | Form 10-K (filed 2019-02-27) ↗ |
| FY2017 | Dec 31, 2017 | 261 | -36.7% | Form 10-K (filed 2019-02-27) ↗ |
| FY2016 | Dec 31, 2016 | 412 | – | Form 10-K (filed 2019-02-27) ↗ |
Cite this data
StockData. (2026). Merck Dulera ($M), annual FY2016–FY2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-dulera-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.